UPDATE 2-AstraZeneca to test impact of cancer drug Calquence on coronavirus patients

AstraZeneca Plc said on Tuesday it would start a clinical trial of its cancer drug Calquence to assess its potential to control the exaggerated immune system response associated with COVID-19 infection in severely ill patients.